Soligenix, Inc.

NasdaqCM:SNGX Voorraadrapport

Marktkapitalisatie: US$8.8m

Soligenix Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Soligenix has been growing earnings at an average annual rate of 7.8%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been declining at an average rate of 45.6% per year.

Belangrijke informatie

7.8%

Groei van de winst

33.3%

Groei van de winst per aandeel

Biotechs Groei van de industrie17.0%
Inkomstengroei-45.6%
Rendement op eigen vermogen-203.3%
Nettomarge-1,423.8%
Laatste winstupdate30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

Soligenix: A Biotech Bargain Ready To File For Approval In Cutaneous T-Cell Lymphoma

Oct 05

U.S. FDA awards $2.6M grant for expanded study of Soligenix's HyBryte for skin cancer

Sep 12

Soligenix announces $2.6M FDA grant to further study blood cancer candidate

Sep 06

Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?

Sep 06
Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?

Soligenix GAAP EPS of -$0.06 beats by $0.03, revenue of $0.4M beats by $0.2M

Aug 12

Soligenix, SERB Pharma team up to develop therapy for ricin poisoning

Jul 25

Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?

Apr 22
Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?

Is Soligenix (NASDAQ:SNGX) Using Too Much Debt?

Jan 03
Is Soligenix (NASDAQ:SNGX) Using Too Much Debt?

Shareholders May Find It Hard To Justify Increasing Soligenix, Inc.'s (NASDAQ:SNGX) CEO Compensation For Now

Sep 17
Shareholders May Find It Hard To Justify Increasing Soligenix, Inc.'s (NASDAQ:SNGX) CEO Compensation For Now

Health Check: How Prudently Does Soligenix (NASDAQ:SNGX) Use Debt?

Aug 30
Health Check: How Prudently Does Soligenix (NASDAQ:SNGX) Use Debt?

Is Soligenix (NASDAQ:SNGX) Weighed On By Its Debt Load?

May 08
Is Soligenix (NASDAQ:SNGX) Weighed On By Its Debt Load?

What Type Of Returns Would Soligenix's(NASDAQ:SNGX) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Mar 16
What Type Of Returns Would Soligenix's(NASDAQ:SNGX) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Soligenix inks supply and distribution deal for SGX301 companion light device in cancer

Jan 07

Soligenix receives $1.5M grant advancing COVID-19 vaccine development

Dec 28

Opbrengsten en kosten

Hoe Soligenix geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

NasdaqCM:SNGX Opbrengsten, kosten en inkomsten (USD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 240-753
31 Mar 241-743
31 Dec 231-643
30 Sep 231-855
30 Jun 231-1056
31 Mar 231-1057
31 Dec 221-1478
30 Sep 221-1578
30 Jun 221-1579
31 Mar 221-1579
31 Dec 211-1358
30 Sep 211-1359
30 Jun 211-1258
31 Mar 212-1248
31 Dec 202-18415
30 Sep 203-15313
30 Jun 203-16314
31 Mar 204-15314
31 Dec 195-938
30 Sep 195-1038
30 Jun 195-937
31 Mar 195-837
31 Dec 185-937
30 Sep 186-836
30 Jun 186-735
31 Mar 185-836
31 Dec 175-736
30 Sep 176-534
30 Jun 177-635
31 Mar 179-434
31 Dec 1610-334
30 Sep 1612-545
30 Jun 1613-145
31 Mar 1611-446
31 Dec 159-845
30 Sep 158-435
30 Jun 157-1135
31 Mar 157-835
31 Dec 147-735
30 Sep 146-834
30 Jun 144-1034
31 Mar 143-1235
31 Dec 133-1035

Kwaliteitswinsten: SNGX is currently unprofitable.

Groeiende winstmarge: SNGX is currently unprofitable.


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: SNGX is unprofitable, but has reduced losses over the past 5 years at a rate of 7.8% per year.

Versnelling van de groei: Unable to compare SNGX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Winst versus industrie: SNGX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Rendement op eigen vermogen

Hoge ROE: SNGX has a negative Return on Equity (-203.26%), as it is currently unprofitable.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden